Medicare's new GLP-1 Bridge program, running from July 2026 to December 2027, offers eligible enrollees specific weight-loss GLP-1 drugs for a $50 copay. This initiative is expected to boost prescription volumes for Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) among Medicare beneficiaries, despite negotiated lower per-prescription economics.
Medicare is launching a temporary 'GLP-1 Bridge' program from July 2026 to December 2027, allowing eligible Part D members to access specific weight-loss GLP-1 medications (Wegovy, Zepbound) for a $50 monthly copay. This is significant because Medicare previously refused to cover GLP-1s solely for weight loss. The program creates a new subsidized demand channel for Novo Nordisk (NVO) and Eli Lilly (LLY), potentially boosting their obesity drug sales among Medicare beneficiaries. However, the government negotiated lower per-prescription economics, and the program has an expiration date, creating both a short-term revenue opportunity and a long-term uncertainty for these drugmakers. Humana (HUM) is involved in processing approvals, indicating an administrative role.